163 related articles for article (PubMed ID: 31702665)
21. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W; Li Z; Zheng Z; Wu X
Cancer Med; 2020 Aug; 9(16):5899-5907. PubMed ID: 32627959
[TBL] [Abstract][Full Text] [Related]
22. Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study.
Li YH; Zhou Y; Wang YW; Tong L; Jiang RX; Xiao L; Zhang GJ; Xing SS; Qian F; Feng JQ; Zhao YL; Wang JG; Wang XH
Medicine (Baltimore); 2018 Sep; 97(36):e12222. PubMed ID: 30200142
[TBL] [Abstract][Full Text] [Related]
23. S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.
Zhang C; Yu GM; Zhang M; Liu D
Medicine (Baltimore); 2020 Jan; 99(1):e18691. PubMed ID: 31895837
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
25. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
[TBL] [Abstract][Full Text] [Related]
26. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
Bellmunt J; Théodore C; Demkov T; Komyakov B; Sengelov L; Daugaard G; Caty A; Carles J; Jagiello-Gruszfeld A; Karyakin O; Delgado FM; Hurteloup P; Winquist E; Morsli N; Salhi Y; Culine S; von der Maase H
J Clin Oncol; 2009 Sep; 27(27):4454-61. PubMed ID: 19687335
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of apatinib combined with S-1 for advanced gastric cancer: A systematic review and meta-analysis.
Chen X; Wan L; He Y; Zhang Q; Zheng X
Medicine (Baltimore); 2024 May; 103(21):e38272. PubMed ID: 38787998
[TBL] [Abstract][Full Text] [Related]
28. Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study.
Lin H; Han D; Fu G; Liu C; Wang L; Han S; Liu B; Yu J
Onco Targets Ther; 2019; 12():1681-1689. PubMed ID: 30881023
[TBL] [Abstract][Full Text] [Related]
29. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
[TBL] [Abstract][Full Text] [Related]
30. Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial.
Wang KX; Cui TY; Yang XD; Wang GQ; Jiang QS; Sun H; Jiang NY; Yong XM; Shi CB; Ding YB; Chen XF; Fang YY
Onco Targets Ther; 2021; 14():4859-4865. PubMed ID: 34584426
[TBL] [Abstract][Full Text] [Related]
31. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.
Liu X; Qin S; Wang Z; Xu J; Xiong J; Bai Y; Wang Z; Yang Y; Sun G; Wang L; Zheng L; Xu N; Cheng Y; Guo W; Yu H; Liu T; Lagiou P; Li J
J Hematol Oncol; 2017 Sep; 10(1):153. PubMed ID: 28870253
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
Guo Y; Tang J; Huang XE; Cao J
Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Wu Q; Fu Y; Wen W; Xi T; Zhao G
J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
[TBL] [Abstract][Full Text] [Related]
34. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and biomarker exploration of camrelizumab combined with apatinib in the treatment of advanced primary liver cancer: a retrospective study.
Zeng Z; Jiang Y; Liu C; Zhu G; Ma F; Yang L; Qiu J; Tang J; Ye X; Peng T; Zeng J; Ma J
Anticancer Drugs; 2021 Nov; 32(10):1093-1098. PubMed ID: 34232941
[TBL] [Abstract][Full Text] [Related]
36. Treatment effect of apatinib combined chemotherapy as second-line or above therapy in patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.
Zhang F; Yin Y; Ni T; Zhang M; Zhou Z; Sun X; Kuang W; Li P
Pharmazie; 2020 Aug; 75(8):389-394. PubMed ID: 32758339
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
Zhang X; Xiong Y; Xia Q; Wu F; Liu L; Zhou Y; Zeng L; Zhou C; Xia C; Jiang W; Liao D; Xiao L; Liu L; Yang H; Guan R; Li K; Wang J; Lei G; Zhang Y; Yang N
JAMA Netw Open; 2020 Mar; 3(3):e201226. PubMed ID: 32191330
[TBL] [Abstract][Full Text] [Related]
39. Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial.
Zhou N; Zhang C; Liu D; Liu K; Wang G; Zhu H; Zhang J; Jiang M; Liu N; Zhang X
Oncologist; 2021 Mar; 26(3):e374-e381. PubMed ID: 33244809
[TBL] [Abstract][Full Text] [Related]
40. Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.
Deng YY; Jiang DY; Zhu PF; Lu H; Liu Q; Zhang X; Pan SY; Chen ZL; Yang L
World J Surg Oncol; 2023 Apr; 21(1):129. PubMed ID: 37041581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
